Prisinformation från TradingView

Bolagspresentation:

Nyhetsflöde Ossdsign

Related articles:
5/2/2024 1:12:31 PM - OssDsign: Exceptional sales growth looks to continue - SEB - In our view, on the basis of evidence for growing demand for Catalyst and OssDsign's strong ability to continuously add further hospital approvals, we see reasons to believe OssDsign's strong sales momentum will remain. Scalability should improve based on the closure of the Cranial PSI business line, we believe, provided sales commissions fall as a percent of sales. According to management, gross margins will rise towards 90% in 2024, which should provide support.
4/29/2024 7:56:22 AM - Ossdsign får tillgång till 100 nya sjukhus inom U.S. Veteran Affairs - Ossdsign har tecknat ett nytt avtal med U.S. Veteran Affairs som omfattar ytterligare cirka 100 ortopediska VA-sjukhus över hela USA. Bolaget uppger i ett pressmeddelande att det innebär utökad tillgång till den amerikanska militära marknaden.
4/11/2024 12:35:06 PM - Carnegie justerar motiverat värde för Ossdsign - Carnegie justerar det motiverade värdet för Ossdsign till intervallet 10-13 kronor (9-13), framgår det av en uppdragsanalys.
4/2/2024 5:04:49 AM - Ossdsign tecknar avtal med Premier i USA för nanosyntetiskt bengraft - Ossdsign har tilldelats ett nytt gruppavtal (GPO) för ben- och benersättningsprodukter med amerikanska Premier, Inc, som samlar cirka 4 350 amerikanska sjukhus och vårdgivare. Avtalet gäller i tre år med start 1 juli i år. Det framgår av ett pressmeddelande.
3/7/2024 7:49:35 AM - Ossdsign: Update after HC seminar and news in the spinal fusion market - Carnegie - OssDsign’s participation at Carnegie’s healthcare seminar
2/29/2024 8:09:40 AM - Ossdsign utser ny CTO - Ossdsign har utsett Tom Buckland till ny teknikchef, CTO.
2/7/2024 8:29:23 AM - OssDsign Q4: Sales will go up, and costs will go down - Redeye - Redeye’s initial take on the OPEX in Q4 being temporarily high is bolstered after a deeper dive into the report. As such, we repeat our take on OPEX coming down significantly from these levels already in Q1 2024e. We make some positive sales estimate revisions but leave our fair value range practically untouched.
2/7/2024 6:26:31 AM - OssDsign: Full focus on Catalyst going forward - ABG - Small miss on underlying PTP in Q4<br>Higher non-recurring items than expected<br>Fair value range down to SEK 9-16 (9-17)
2/7/2024 6:25:05 AM - OssDsign: All it took was a Catalyst - SEB - OssDsign now enters 2024 with a clean sheet, with a high growth and high margin product in Catalyst that grew 256% y/y and boosted underlying gross margin to 83% from 64% in Q4/22. The gross margin should continue to increase in 2024 and reach levels of 90% or above within a couple of quarters together with a growth profile that looks very attractive. We reiterate our DCF-based fair value range of SEK 8-13 per share.
2/6/2024 7:51:08 AM - OssDsign Q4: Sales on point, but costs surprised - Redeye - Redeye sees a Q4 with sales coming in according to our estimates, but we note that costs came in higher than expected (both in COGS and OPEX: one-offs related to Cranial and other temporary).
2/6/2024 7:12:15 AM - OssDsign Q4: Catalyst continue to accelerate - SEB - OssDsign reported Catalyst sales of SEK 26.8m (10% vs SEB 24.4) 256% y/y growth, driven in part by extraordinary large orders of c. SEK 4m (we expected SEK 4.5m). Strong quarter was expected as the two first months had been pre-announced. On the cost side, NRIs from Cranial PSI discontinuation were SEK 20m (25% vs SEB 16m) and overall opex was 24% higher than our estimates. Mixed report given the strong top line but higher-than-expected costs. Mid-point SEK 10.
2/6/2024 6:21:18 AM - Ossdsign ökar omsättning men engångskostnader pressar ned resultatet - Ossdsign ökar omsättningen rejält men resultatet tyngs av bland annat engångskostnader och avvecklingskostnader.
1/31/2024 10:15:12 AM - OssDsign: Redeye Q4 2023e preview - Redeye - Redeye shares its preview of OssDsign’s Q4 2023e results, due on February 6.
1/29/2024 7:26:32 AM - Carnegie inleder bevakning av Ossdsign - ser motiverat värde om 9-13 kronor per aktie - Carnegie inleder bevakning av Ossdsign. Det motiverade värdet sätts till 9-13 kronor, enligt en färsk uppdragsanalys. Stängningskursen från i fredags är 9,16 kronor.
1/25/2024 6:21:11 AM - OssDsign: Analyst - ABG - Q4'23 results due 6 February<br>Already pre-announced strong sales for Oct-Nov<br>Fully focused US orthobiologics company as of New Year
1/24/2024 11:18:40 AM - Ossdsign får studieresultat publicerade i vetenskaplig tidskrift - Ossdsign har fått de tidigare kommunicerade, tolv månadersresultaten från den kliniska studien <br>Top Fusion publicerade i den vetenskapliga tidskriften Biomedical Journal of Scientific &amp; Technical Research. Det framgår av ett pressmeddelande.
1/15/2024 6:34:53 AM - OssDsign: Break a leg - SEB - Given that OssDsign released a statement expecting Q4 sales to exceed market estimates early in the quarter, we feel quite confident about Catalyst showing strong growth numbers. We estimate 224% y/y growth for Catalyst with a healthy contribution from some extraordinarily large orders from a large hospital system, and strong underlying development that is keeping the growth story alive. We reiterate our DCF equity mid-point value of SEK 10.
1/10/2024 12:46:27 PM - OssDsign: Easier markets and own actions should lift 2024 - SEB - At SEB's Nordic seminar, Verkkokauppa's CEO Panu Porkka said the single most important market datapoint was consumer confidence: when Finnish consumer confidence revives, so should demand. This should happen during 2024. The company is working on new and profitable revenue streams and to exploit its strong position online in Finland. With the shares at a 5Y low and key peers' shares recovering, we think Verkkokauppa's share price should follow suit.
1/10/2024 10:56:46 AM - OssDsign: Growth story intact - SEB - At SEB's Nordic Seminar, OssDsign's CEO Morten Henneveld talked about the study results released yesterday that confirmed the pre-clinical data. The TOP FUSION study is a first-in-patient study and the results showed a 93% fusion rate after 12 months. It is a small study, but together with the safety report and 2,000 patients treated, it gives an indication that the product is working as intended.
1/9/2024 2:23:34 PM - OssDsign: Promising data from TOP FUSION’s top-line results - Redeye - Redeye embraces the reported data from OssDsign’s TOP FUSION clinical study, and we await further peer-reviewed publication in the intended journal. We anticipate a continuous positive share price development on the back of the news and ahead of the Q4 2023 report in mid-February. We reiterate our SEK15 base case, representing a c60% upside, which we believe should close during the year.
1/9/2024 1:56:14 PM - Positiva data för Ossdsigns studie har skickats in till en vetenskaplig tidskrift - Ossdsign meddelat att positiva data från den kliniska studien TOP FUSION har skickats in till en vetenskaplig tidskrift som är peer-reviewed.
12/7/2023 4:15:31 PM - Redeye ser positivt på Ossdsigns ökade intäkter under Q4 - upprepar motiverat värde - Ossdsigns tillkännagav igår onsdag att bolagets intäkter under det fjärde kvartalet överstiger marknadens förväntningar. Redeye ser positivt på utvecklingen för bolaget och upprepar det motiverade värdet om 15 kronor per aktie i ett basscenario, enligt en färsk uppdragsanalys.
12/7/2023 2:22:24 PM - OssDsign: Higher-than-expected Q4 preliminary sales - Redeye - Redeye is encouraged by the preliminary Q4 (Oct-Nov) sales, and we positively review the sales estimates for Catalyst for 2023e-2025e. While a good sign on the roll-out of Catalyst (further increasing our confidence in our take on the case), we reiterate our fair value range. We highlight the significant discount OssDsign is trading at compared to its peers, further cementing our thesis of a strong share price development into next year.
12/7/2023 8:30:37 AM - SEB höjer Ossdsigns motiverade värde efter omvänd vinstvarning - Efter att Ossdsign igår släppt en omvänd vinstvarning om att intäkterna väntas vara högre i Q4 än marknadens förväntningar väljer SEB att höja sitt motiverade värde för aktien till 10 kronor (9). Det framgår av en uppdragsanalys.
12/7/2023 7:30:21 AM - OssDsign: A welcome surprise - SEB - OssDsign announced a reverse profit warning, stating that it expects Q4 revenue to exceed market potential. October-November sales amounted to SEK 25.2m with SEK 18.8m coming from Catalyst. We lift our Q4 Catalyst sales estimate by 29% to SEK 24.5m and 2024E-25E Catalyst sales by 13%. The strong performance is due in part to extraordinary large orders from one hospital system. We lift our mid-point equity value to SEK 10 (9).
12/6/2023 8:01:32 AM - OssDsign - Analyst - ABG - Positive sales update for Q4<br>Oct-Nov sales of 25.2m (ABGSCe Q4 SEK 24)<br>Implied upside of 13% to our FY '23e sales estimates
12/6/2023 7:09:33 AM - Ossdsigns intäkter i fjärde kvartalet överstiger marknadens förväntningar - Medicinteknikbolaget Ossdsign aviserar att bolaget förväntar sig att intäkterna för det fjärde kvartalet 2023 kommer att överträffa marknadens förväntningar. Det framgår av ett pressmeddelande.
11/30/2023 5:39:12 AM - SEB Venture Capital gör exit i Ossdsign - säljer aktierna till 11,9 procents rabatt - SEB Venture Capital har sålt sitt innehav på cirka 7,6 procent av aktierna i medicinteknikbolaget Ossdsign, enligt Bloomberg News. Aktierna såldes för 6,1 kronor styck, vilket motsvarar en rabatt på 11,9 procent jämfört med Ossdsigns senaste stängningskurs.
11/29/2023 4:29:40 PM - Styrelseledamot köper aktier i Ossdsign för 0,15 miljoner kronor - Anders Qvarnström har per den 28 november köpt 22 000 aktier i Ossdsign där han är styrelseledamot. Aktierna köptes till kursen 6,95 kronor per aktie, en affär på sammanlagt 152 900 kronor.
11/22/2023 10:42:41 AM - Penser upprepar motiverat värde för Ossdsign - Erik Penser Bank väljer att upprepa sitt motiverade värde för Ossdsign på 13-14 kronor, framgår det av en uppdragsanalys.
11/22/2023 10:03:58 AM - OssDsign: Benhård tillväxt - Penser - Catalyst växte med 155% under Q3’23 OssDsigns nettoomsättning för det tredje kvartalet 2023 uppgick till 31,7 mkr, vilket motsvarar 81% i tillväxt. USA levererade 132% i tillväxt, vilket innebär sex kvartal i rad med tresiffrig tillväxt i den marknaden. Med det så ökade också USA:s andel av global försäljning till 79%. Det var fortsatt acceleration med 155% tillväxt inom ortobiologi (Catalyst), som nu utgör 53% av koncernens totala försäljning. Bruttomarginalen fortsatte utvecklas positivt under kvartalet och nådde 80% (68%), drivet av ortobiologi.
11/22/2023 8:16:37 AM - SEB upprepar motiverat värde för Ossdsign - kliniska data potentiell trigger under 2024 - SEB upprepar sitt motiverade värde om 9 kronor för Ossdsign, framgår det av en uppdragsanalys.
11/22/2023 7:54:18 AM - OssDsign Q3: Catalyst is growing as expected - Redeye - Redeye returns with more insights on the Q3 report, and we continue to feel confident in OssDsign’s capabilities in increasing Catalyst sales in the coming quarters. We also highlight next year’s clinical data publications as share price drivers. Following the report, we make no particular changes to our estimates or valuation.
11/22/2023 7:45:23 AM - OssDsign: Growing above expectations - SEB - OssDsign reported Q3 Catalyst sales of SEK 16.7m (+7% vs SEBe SEK 15.9m), up 155% y/y. Our 2024E-25E Catalyst sales forecasts are mostly unchanged (negative forex impact), which implies organic growth of 70% for 2024 and 46% for 2025. We believe this path should take OssDsign into positive cash flow territory by 2026 and reiterate our mid-point equity value of SEK 9/share. We think 2024 could be exciting with clinical data a potential trigger.
11/22/2023 6:26:41 AM - OssDsign: Analyst - ABG - 74% FX-adj. sales growth in Q3, mainly driven by Catalyst<br>Balance sheet strengthened through directed share issue<br>Fair value range raised to SEK 10-17 (9-15)
11/21/2023 11:45:07 AM - Ossdsign - Q3 Presentation 2023 - Today OssDsign with CEO Morten Henneveld and CFO Anders Svensson presented the Q3 report for 2023.
11/21/2023 8:02:16 AM - SEB upprepar motiverat värde för Ossdsign - spår att konsensus för Catalyst höjs - Ossdsign uppvisade ett bra momentum i det tredje kvartalet för Catalyst, vars omsättning ökade med 155 procent mätt som årstakt. Det skriver SEB i en uppdragsanalys efter morgonens rapport.
11/21/2023 7:52:50 AM - OssDsign Q3: Initial take – Sales growing strongly with increasing operating leverage - Redeye - Redeye provides its initial comment on OssDsign’s Q3 report. Sales of Catalyst came in c10% above our expectations and demonstrates a significant growth of 155%. With an 80% gross margin, we note an increasing operating leverage. We anticipate a positive share price reaction today of 5-10%.
11/21/2023 7:52:26 AM - OssDsign Q3: Record quarter for Catalyst, 155% growth y/y - SEB - Catalyst sales of SEK 16.7m (7% vs SEB 15.6) corresponding to 155% y/y growth was strong. The good momentum continues and more IDNs seems to be driving this. A new reporting style, more transparent, is welcomed as it gives us and investors a better view of the cost base. We note that R&amp;D expenses are up 50% y/y which we believe has to do with enrollment to the clinical registry. We reiterate our DCF mid-point of SEK 9.
11/21/2023 7:08:47 AM - Ossdsign ökar omsättning och förbättrade resultatet - Ossdsign, som är ett av Karolinska Developments portföljbolag, redovisar kraftigt ökande omsättning under tredje kvartalet jämfört med samma period året innan. Rörelseförlusten minskade.
11/16/2023 1:34:46 PM - OssDsign: Redeye Q3 2023e preview - Redeye - Redeye shares its preview of OssDsign’s Q3 2023e results, due November 21.
11/14/2023 6:12:57 AM - OssDsign: All focus on Catalyst - SEB - We estimate Q3 Catalyst sales of SEK 15.6m, corresponding to y/y growth of 138%, driven by continued uptake and increased use, but the main driver being new users. We account for a SEK 15m one-off cost related to the ongoing discontinuation of Cranial PSI but expect a limited impact on sales due to the announcement coming late in Q3. The Q4 Cranial sales decrease is tough to assess as lead times and timing can affect it. We reiterate our mid-point of SEK 9.
10/10/2023 6:53:43 AM - Ossdsign: Twist and turns - SEB - OssDsign has decided to discontinue all operations related to Cranial PSI and focus solely on being an orthobiologics company. We update our estimates accordingly, removing all Cranial PSI sales from Q1/24, which impacts sales by -38% for 2024E and by -31% for 2025E. We reduce our opex assumptions and adjust the number of shares to reflect the directed share issue. This lowers our mid-point equity value to SEK 9 (12) per share.
9/28/2023 12:05:56 PM - OssDsign: Fully funded and fully focused - Redeye - Redeye returns with a more in-depth take on the discontinuation of Cranial. We update our financial forecasts on all time horizons, rendering a new fair value range. We are encouraged about the strategy shift and glad to see it initiated earlier than we expected. With an entirely focused orthobiologics business and the SEK150m directed share issue, the equity story is strengthened, and the share should see an upward momentum shortly.
9/28/2023 9:01:13 AM - OssDsign: Strategiskifte och nyemission - Penser - Strategiskifte OssDsign kommer nu att fokusera enbart på kommersialiseringen av OssDsign Catalyst i USA, som utgör mer än 70% av den globala marknaden för spinala bengraft och kännetecknas av stora volymer och mycket attraktiv prissättning. Marknadssegmentet för OssDsign Catalyst värderas till 1,8 miljarder USD, med en årlig tillväxttakt om 8%. Riktad nyemission Bolaget har genomfört en riktad nyemissionen till kurs 5,70, vilket motsvarar 6% rabatt jämfört stängningskurs 26/9. Bolaget tillförs 150 mkr före transaktionskostnader. Den riktade emissionen medför en utspädning om 26,9% av antalet aktier och röster i bolaget. Investerare i den riktade emissionen innefattar såväl befintliga aktieägare som nya svenska och internationella institutionella investerare, såsom TAMT AB, Karolinska Development AB, Adrigo Asset Management, Lancelot Asset Management AB, Linc AB och FSG Fund II AB. Motiverat värde 13–14 SEK/aktie Vi har nu modellerat OssDsign som ett renodlat ortobiologi-bolag fokuserat på USA-marknaden. Efter att ha justerat för utspädning i samband med emissionen så uppgår vårt motiverade värde till 13–14 kr/aktie. Värderingen baseras på en diskonterad kassaflödesvärdering med ett avkastningskrav (WACC) på 14%. Därtill finner vi stöd i värderingen när vi jämför med hur bolag verksamma i Ortobiologi värderas på Stockholmsbörsen.
9/28/2023 8:18:02 AM - OssDsign: Value accretive shift in strategy - ABG - Value accretive shift in strategy<br>Directed share issue of SEK 150m<br>Fair value range up to SEK 9-15 (from 6-15)
9/27/2023 6:43:40 AM - OssDsign: Discontinuing Cranial and a directed share issue - Redeye - Redeye welcomes the discontinuation of the cranial implant, freeing up resources for the company to focus entirely on its Catalyst product. With the SEK150m (before transaction costs) now also raised in a direct share issue, we believe it has a good chance of reaching a positive cash flow on the existing cash position. We will return with an update shortly, presenting our new financial estimates and fair value range. On the back of the news, we expect the share to react positively today, around 10% up.
9/27/2023 6:36:04 AM - OssDsign: Exit from cranial - ABG - • Focus on orthobiologics going forward<br>• New financial targets and rights issue<br>• Expected to be accretive to earnings already in 2024
9/27/2023 5:45:26 AM - Ossdsign gör riktad nyemission - teckningskurs 5,7 kronor - Karolinska Developments portföljbolag Ossdsign genomför en riktad nyemission om drygt 26,3 miljoner aktier till en teckningskurs om 5,7 kronor per aktie, framgår det av ett pressmeddelande. Baserat på gårdagens stängningskurs motsvarar det en rabatt på runt 6,25 procent.
9/27/2023 5:38:59 AM - OssDsign: Updated strategy and directed share issue of SEK 150m - SEB - OssDsign has updated its strategy and decided to discontinue the Cranial PSI business and focus solely on orthobiologics. All already planned surgeries with Cranial PSI in 2023 will be delivered to customers to avoid a negative impact on patients. This also results in all sales coming from the US market from 2024 forward. OssDsign expects to save SEK 30-40m in opex annually from the discontinuation of Cranial PSI. Our mid-point equity value of SEK 12 is under review.
9/19/2023 6:09:04 AM - OssDsign: Expanded FDA clearance - SEB - Following the reported milestone of 2,000 patients treated with OssDsign Catalyst and the expanded FDA clearance, we lift our short-term and long-term earnings estimates. The milestone implies a significantly higher run rate in Q3 than we previously assumed, and the expanded FDA clearance should open new doors and increase the adoption rate. We reiterate our DCF-based mid-point equity valuation of SEK 12 per share.
9/18/2023 10:45:54 AM - OssDsign: FDA expansion for Catalyst is huge - Redeye - Redeye is enthusiastic by today’s news of the FDA expanding the approval for Catalyst to interbody cages in spinal fusion. The approval enables full on-label usage in spinal surgery and positions OssDsign as one of only three companies with such an approval. Naturally, the company’s value proposition is significantly increased, and its commercialisation should see a tailwind as we advance. We reiterate our SEK13 base case.
9/18/2023 7:43:43 AM - OssDsign: Catalyst receives new FDA clearance - SEB - FDA has approved OssDsign Catalyst for use in interbody cages in spinal surgery. This will allow surgeons to use Catalyst on-label in the interbody space. Today a lot of the synthetic bone graft is believed to be used off-label which represents a risk to the hospital and surgeons. We view this news as very positive as it will most likely increase the number of hospital approvals which should lead to more users and larger volumes. Our mid-point of SEK 11 is under review.
9/4/2023 5:36:56 AM - OssDsign: Analyst - ABG - 79% FX-adj. sales growth in Q2, mainly driven by Catalyst<br>Opex stabilising<br>Fine-tune fair value range to SEK 6-15
8/24/2023 5:38:29 AM - OssDsign: Catalyst sets up for a turnaround - Redeye - Redeye raises its base case following a case review of OssDsign and we positively reconsider its commercial prospects for Catalyst. Once the cash position is sorted (we anticipate an equity issue in the coming months), we believe investors will begin recognizing the new equity story of OssDsign.
8/23/2023 9:29:25 AM - OssDsign: 148% tillväxt i USA - Penser - 148% tillväxt i USA. OssDsigns nettoomsättning under Q2 uppgick till 24 mkr vilket motsvarar 92% tillväxt (79% i fasta valutakurser), 148% tillväxt i USA. Bolaget har sedan lanseringen utav Catalyst i USA i augusti 2021 lyckats vinna ett antal långsiktiga kontrakt med stora sjukhussystem, så kallade Integrated Delivery Networks (IDNs). Dessa är nätverk av vårdenheter och institutioner som erbjuder ett komplett utbud av vårdtjänster och är en mycket viktig del av det amerikanska sjukvårdssystemet. Avtalen ökar tillgängligheten till Catalyst i USA och breddar bolagets kommersiella möjligheter avsevärt.
8/23/2023 5:22:26 AM - OssDsign: Accelerating into leverage - SEB - OssDsign’s Q2 sales were broadly in line with our estimate but its operating profit was slightly better than we expected. There were good signs of leverage coming through thanks to continued momentum in Catalyst sales (39% sequential growth). The growth story has played out nicely over the past year and we expect leverage to follow. We raise our DCF-based mid-point valuation to SEK 12 (11) per share.
8/22/2023 11:19:08 AM - OssDsign - Q2 Presentation 2023 - OssDsign - CEO Morten Henneveld and CFO Anders Svensson presents Q2 2023 and answer questions from the viewers.
8/22/2023 6:34:11 AM - OssDsign Q2: Sales 3% above our expectations, improved gross margin - SEB - OssDsign continues to deliver strong sales numbers with US sales growth of 148% y/y and total organic growth of 79% y/y. Catalyst sales continues to develop strongly and have now surpassed Cranisl PSI as the largest revenue contributor, amounting to 51% of sales. Gross margin came in at 77% (Q2/22:68%), first time the company discloses. The strong sales development continues. We reiterate our DCF-based mid-point equity value of SEK 11 per share.
7/13/2023 10:10:23 AM - OssDsign: Spine-tingling acceleration - SEB - We estimate Q2 sales of SEK 23m for the quarter, where we expect Catalyst to continue to develop strongly in the US. We expect y/y growth of 86%, mostly driven by the US where we estimate sales growth of 122%. We make minor adjustments to our estimates, raising expectations in the US, which explains most of our estimate changes. We reiterate our DCF-based mid-point value of SEK 11 per share.
5/25/2023 5:29:07 AM - OssDsign: Signal of Catalyst accelerating in Q2 - ABG - Sales up 203% y-o-y, and 6% better than ABGSCe<br>1,000 patients treated signals 25% Catalyst q-o-q growth in Q2<br>We raise sales by 3-2% for '23e-'24e
5/24/2023 9:13:55 AM - OssDsign: Exponentiell tillväxt för Catalyst - Penser - USA-försäljning upp med 339% OssDsigns nettoomsättning för det första kvartalet uppgick till 21,5 SEKm, vilket motsvarar en omsättningstillväxt på 203% jämfört med Q1 2022, eller 177% vid konstanta växelkurser. Drivkrafterna bakom denna tillväxt är försäljningen av Catalyst i USA. Total försäljning i USA ökade med 399% jämfört Q1 2022. USA-marknaden utgör nu 65% av bolagets försäljning. Även försäljningen av Cranial PSI visar hälsosam tillväxt, växte 74% i övriga världen.
5/24/2023 5:39:29 AM - OssDsign Q1: Steep acceleration of sales - Redeye - Redeye sees another quarter in which OssDsign rolls out Catalyst full steam ahead. Sales were in line with our relatively optimistic forecast, with a stronger gross margin than anticipated. Our thesis of the company being a solid high-growth play is strengthened by the report. We reiterate our base case and note a hefty discount to its peers’ multiples.
5/24/2023 5:37:41 AM - OssDsign: Start believing this growth journey - SEB - OssDsign reported 177% organic growth y/y in Q1, with another quarter of the US leading the way where sales grew 399% y/y. Sales were in line with our estimate, but operating profit was well below due to an incorrect assumption from our side on the FX hedge that has been yielding high returns throughout 2022. We now reset our profitability expectations for 2023-25 but raise sales 6% for 2023E. We reiterate our mid-point value of SEK 11.
5/23/2023 6:59:08 AM - OssDsign Q1: 177% organic growth y/y - SEB - OssDsign reported strong organic growth of 177%, driven by both Catalyst and Cranial PSI. Cranial PSI doubled sales y/y thanks to strong development in France and Germany. Sales was SEK 21.5m (1.1% vs SEB 21.2m) but EBIT was well below our expectations. Cash burn increased to SEK 29m due to larger than normal working capital affects. US sales were up 399% y/y which shows the continued acceleration of Catalyst. We reiterate our mid-point valuation of SEK 11 per share.
5/3/2023 5:38:41 AM - OssDsign: Rapid growth seems here to stay - SEB - We expect Q1/23 sales of SEK 21m, y/y growth of 200% from a pandemic-affected quarter last year. Both Cranial PSI and Catalyst should do well on the back of some recent positive news and signs of elective care gradually improving. We increase our Q1/22 sales estimate by SEK ~2m as we expect Cranial to perform well in Germany and France, boosting EU sales. We reiterate our DCF-based mid-point of SEK 11 per share.
2/22/2023 10:11:39 AM - OssDsign: Inne i kraftfull tillväxtfas - Penser - Rapportkommentar Omsättningen för Q4 blev 19,9 mkr (9,2), upp 117% (89% CER). För helåret slutade intäkterna på 57 mkr, en tillväxt på 80% (62 CER). Resultatet efter skatt var -31,9 mkr (-28,7) för fjärdekvartalet. Likvida medel vid periodens slut var 124,6 mkr.
2/22/2023 6:16:16 AM - OssDsign: Beats expectations with growth of 117% - ABG - Sales 15% better, EBIT 0% vs. ABGSCe<br>We cut '23-'24e sales by 5-6%<br>Lowered fair value range to SEK 6-16 (8-21)
2/22/2023 6:14:35 AM - OssDsign: Hitting a growth spurt - SEB - OssDsign delivered another quarter of strong growth, with the US being a clear driver with 162% growth y/y. Total sales of SEK 19.9m were in line with our estimates, but opex was higher than expected which resulted in a cash burn of SEK 25m. The company is growing fast, especially in the US where OssDsign has shown sequential growth since Q1/21 (apart from for Q1/22 due to omicron). We reiterate our mid-point equity value of SEK 11.
2/21/2023 11:54:05 AM - Ossdsign - Q4 presentation 2022 - Idag presenterade OssDsign med VD Morten Henneveld &amp; CFO Anders Svensson bolagets rapport för det fjärde kvartalet 2022. Se presentationen via Spotify eller Youtube nedanför:
2/21/2023 7:44:41 AM - Ossdsign: Rapid growth, again - SEB - OssDsign reported sales above our expectations, Net sales were SEK 19.9m (0.4% vs. SEBe of SEK 19.9m) corresponding to y/y growth of 117%. Catalyst sales amounted to SEK 7.5m and represented 38% of total revenues. The company had a one-off related to the revaluation of provisions for contingent consideration in the Sirakoss acquisitions, resulting in net interest expenses of SEK 8.9m. Our mid-point equity value is SEK 11 per share.
2/20/2023 8:21:28 AM - OssDsign: Conditions remain challenging - ABG - Staffing shortages in Q4 likely hurt volumes<br>We cut '22e-'24e sales by 5-20%<br>We have a positive view on Catalyst potential
1/31/2023 7:56:30 AM - OssDsign: A pivotal year ahead - SEB - We believe Q4 will be another quarter of strong growth considering the recent announcement that OssDsign has reached the milestone of 500 patients treated with Catalyst. We forecast Catalyst sales of SEK 8m in Q4/22, an increase of about SEK 1.5m q/q. As we head into 2023, we move closer to seeing clinical data on Catalyst, which we believe is the most important datapoint in 2023. We reiterate our mid-point of SEK 11 per share.
1/12/2023 1:23:33 PM - Ossdsign: Yes, more cash is needed - SEB - At SEB’s Nordic seminar, CEO Morten Henneveld acknowledged that the US market remained problematic, but the Spine(Catalyst) business was more resilient than the CMF market, and that OssDsign would need more cash in the future. He said that the company’s goal was to keep expanding business in the US while still limiting cash burn. On a positive note, momentum has been strong over the last two quarters and Catalyst sales are accelerating with increase in recurring customers.
1/12/2023 9:16:40 AM - OssDsign: Yes, more cash is needed - SEB - At SEB’s Nordic seminar, CEO Morten Henneveld acknowledged that the US market remained problematic and that OssDesign would need more cash from shareholders in the future. He said that the company’s goal was to increase the number of staff - especially sales people - whilst limiting cash burn. On a positive note, momentum has been strong over the last two quarters and Catalyst sales are accelerating with an increase in the number of recurring customers.
1/5/2023 7:07:16 AM - OssDsign: Promising first patient report - Redeye - Redeye is encouraged by the continuous positive news flow related to Catalyst, and we embrace the just-announced first patient report from the TOP FUSION clinical trial. We summarise some key parts of the case as we go into 2023 and reiterate our SEK9.5 base case.
1/4/2023 4:04:14 PM - Karolinska Developments portföljbolag Ossdsign publicerar patientrapport i vetenskaplig tidskrift - Life science-investmentbolaget Karolinska Developments portföljbolaget Ossdsign har publicerat en första patientrapport efter att en patient stelopererats med Ossdsign Catalyst i den kliniska studien Top Fusion. Artikeln är publicerad i den vetenskapliga tidskriften Biomedical Journal of Scientific &amp; Technical Research och visar på en fullständig ryggradsfusion sex månader efter operationen. Det framgår av ett pressmeddelande.
11/30/2022 12:04:25 PM - OssDsign: Strengthens its balance sheet - Redeye - Redeye leaves a brief comment on OssDsign’s directed share issue rendering an upwards adjustment to our fair value range. We embrace the strengthening of its balance sheet but emphasise that we expect the company to raise further funding in early 2024.
11/30/2022 5:57:38 AM - Karolinska Development tecknade sin andel i Ossdsigns riktade nyemission - Life science-investmentbolaget Karolinska Developments portföljbolag Ossdsign har genomfört en riktad nyemission på 65,5 miljoner kronor före emissionskostnader. Det framgår av ett pressmeddelande.
11/23/2022 12:22:31 PM - OssDsign: Ytterligare ett försäljningsmässigt starkt kvartal - Penser - Rapportkommentar Omsättning för Q3 blev 17,5 mkr (8,9) upp 96% (71% CER). Det är också en ökning jämfört Q2 med 40%. USA-marknaden utgör 62% av gruppens försäljning. Resultat efter skatt var -19,6 mkr (-16,5). Likvida medel vid periodens slut var 88,7 mkr.
11/23/2022 8:57:47 AM - OssDsign: Q3, Catalyst positively surprises, but still a difficult climate - Redeye - Redeye is encouraged by the strong sales development, boosted by Catalyst contributing to c60% of US sales. While its spine product certainly positively surprised us, we emphasise a continuously challenging climate for elective surgeries and restricted hospital access, likely to depress sales in the medium term. We adjust our fair value range downwards following the report.
11/23/2022 8:22:14 AM - OssDsign: On a promising trajectory in the US - ABG - Better sales as US grew 144% on Catalyst success Underlying estimates relatively unchanged Fair value range of SEK 8-21 unchanged Recently launched bone graft continues to outperform OssDsign continues to perform well in the challenging hospital environment. It managed to grow 96% y-o-y and beat ABGSCe by 4% on sales. The US grew by 144%, and this strength was solely driven by Catalyst (bone graft), which had sales of SEK 6.6m in the quarter. It now represents 38% of group sales, and likely 50% of gross profit considering the higher margins. We are encouraged by the initial adoption rate, as there is normally high growth potential in same surgeon sales. Most only change bone graft material in a small share of surgeries to begin with, and we view this as highly supportive for continued growth. Cranial PSI was relatively flat in the US, likely as OssDsign is shifting sales efforts to Catalyst, but showcased high growth of 47% in Europe. We think this is mostly based on penetration in France post- the AP-HP contract win. France is the third-largest market in the Europe, and we see good potential for continued high growth considering low penetration. There were no major surprises on the cost side, and EBIT beat ABGSCe by 14%, showcasing that OssDsign scales well with Catalyst. We think it can achieve a sales CAGR of 66% ’21-25e The performance witnessed in Q3 is supportive of the long-term trajectory depicted by our current estimates. Hence, we only update FX, cutting sales by 2% ’23-24e, and nudge the cost base slightly higher. We now expect a sales CAGR of 66% for ’21-’26e. Given this and the cash position, which is now at SEK 89m, we think a modest cash injection is likely in 23e, supporting a path to positive cash flow in ‘25e. Easing conditions allow for continued momentum We leave our fair value unchanged at SEK 8-21 per share, using a WACC of 11%. We think the company is executing well according to plan and that the setup for continued strong operational performance lo ... Läs mer på ABG Sundal Collier
11/23/2022 6:48:02 AM - OssDsign: Catalyst numbers revealed - SEB - OssDsign reported a strong Q3 with sales 20% above our expectations, driven by very strong momentum for Catalyst in the US. Catalyst was the biggest product in the US in Q3 and stood for 38% of total global sales. We have raised our short-term and long-term assumptions for Catalyst as the sales number was much higher than anticipated. We raise our DCF-based mid-point to SEK 11 (10) per share.
11/22/2022 9:50:39 AM - Ossdsign - Q3 Presentation - The CEO of Ossdsign Morten Henneveld present the report for the third quarter at 11:00 am 22/11.
11/22/2022 8:01:52 AM - Q3: Big sales beat, 20% above expectations - SEB - OssDsign reported Q3 sales of SEK 17.5m which corresponds to a growth of 96% y/y (71% in constant currencies). The company reported a healthy cash position of SEK 88m. OssDsign experienced strong momentum in the US, driven by accelerating Catalyst sales which were 38% of total sales in Q3. Catalyst also became the biggest product in the US, clearly driving the momentum which resulted in growth of 144% y/y in the US.
11/17/2022 2:46:45 PM - OssDsign: Ticking an important box - SEB - OssDsign reported its first post-market safety data, with no device-related complaints nor device-related adverse events. The report revealed valuable information in regard to sales quantities and number of clinics using the product; both numbers were higher than expected. With the Q3 report due next week, we will not be doing any estimate revision for now but note that the risks to our estimates are likely on the upside. Reiterate mid-point of SEK 10 per share.
10/27/2022 7:57:54 AM - OssDsign: Strong momentum, for now - SEB - We expect revenues of SEK 14.6m in Q3, corresponding to growth of 64% y/y, driven by Catalyst sales in the US and strong FX tailwinds. We change our sales estimates by moving sales from Q4 to Q3, leaving our FY 2022 estimates broadly unchanged. Hospitals in the US are struggling which is why we are more cautious on Q4. We reiterate our mid-point value of SEK 10 per share: note that the stock is trading at historical lows around 2x 2023E EV/S.
8/24/2022 1:52:07 PM - OssDsign Q2: A taste of a better market outlook - Redeye - Redeye is encouraged by the strong Q2 sales figures, underpinning our expectations for a strong H2 2022. We anticipate OssDsign’s market outlook to improve in the coming quarters and note a strong US sales development, which we believe will continue as we move throughout the year. We reiterate our SEK 9.5 Base Case. Read more and download the Research Update using the link below.
8/24/2022 1:43:38 PM - OssDsign: USA-marknaden driver kraftig försäljningsökning - Penser - Rapportkommentar OssDsign rapporterade en stark försäljningsökning drivet av USA-marknaden som nu stod för 56% av bolagets totala försäljning under Q2. Omsättningen under kvartalet uppgick till 12,5 MSEK, +63% (49% i fasta valutakurser) jämfört med motsvarande kvartal 2021. Den höga tillväxten beror dels på att sjukhusen återgår till normal aktivitet efter pandemin, men också på en hög efterfrågan på bolagets innovativa benersättningsprodukter.
8/24/2022 8:05:32 AM - OssDsign: Breaking records as Catalyst takes off - ABG - Managed to beat ABGSCe by 18% in tough conditions We lift our ’22e-’24e sales estimates by 5-9% Fair value range unchanged at SEK 8-21 /share
8/23/2022 6:22:16 PM - OssDsign: Staying ahead of the curve - SEB - OssDsign surprised us and the market with sales numbers much stronger than expected. The company reported all-time-high sales of SEK 12.5m vs our estimate of SEB 9.7m, which corresponds to a 63% increase y/y (49% in constant currencies). We argue the company is now starting to gain momentum and is ahead of the normalisation curve, as we still believe there is a long way to go until hospital utilisation is back to normal levels.
8/23/2022 7:25:08 AM - OssDsign Q2: Strong sales growth of 154% y/y in the US - SEB - OssDsign reported strong sales growth,63% y/y (49% constant FX) , with a positive surprise coming from much stronger-than-expected sales growth in the US. CEO Morten Henneveld said that sales were driven by good underlying demand for Cranial PSI with meaningful contribution from Catalyst. We did not expect any meaningful contribution from Catalyst before H2/22 and view this acceleration as a strong positive.
8/10/2022 5:53:05 AM - OssDsign: Returning to sequential growth - SEB - OssDsign, the medtech company which creates patient-specific cranial implants and synthetic bone graft used in i.e., spinal fusion surgery, is looking to us like a good recovery story after the pandemic. We argue that “return to normal” elective care levels will be the main driver. We highlight the large hospital backlogs, which will be the main driver throughout 2022 and 2023. We forecast a return to sequential growth with revenue growth of 26% y-o-y.
6/8/2022 5:49:58 AM - OssDsign: A fusion of disruption and growth - SEB - We initiate coverage of OssDsign, a medtech company poised to benefit from the structural growth trends of an ageing population, stretched healthcare budgets and technological advancement. With a new franchise, Catalyst, giving the company exposure to a substantially larger market, the company looks ready for rapid growth, in our view. Our DCF analysis yields a fair value range of SEK 5-15 per share with a mid-point equity value of SEK 9.
5/30/2022 8:10:49 AM - OssDsign: Past the Omicron bump in the road - ABG - Sales worse than feared, but isolated to Q1 conditions<br> Clinical and commercial progress bodes well for mid-term<br> Reiterate our fair value range of SEK 8-21 per share<br> <br>Weaker sales, but good clinical and commercial progress<br> The impact of Omicron was larger than expected, as surgical volumes and the use of Cranial PSI plummeted. Although the effect was expected and reflected in sales estimates, it was larger than we thought and led to a 22% miss vs. ABGSCe. It was largely due to the ~6 weeks lead time for Cranial PSI, which meant that the elective surgery halt from mid-December to mid-February affected the full quarter. This is a non-recurring effect from external factors, and we do not think it affects the mid-term sales trajectory. Already in Q2’22, we should see a sharp recovery in sales, as elective procedures have recovered to a high level with a large surgical backlog to work through. On the clinical and commercial side, OssDsign has managed to deliver a prestigious contract with the largest hospital network in France (AP-HP), is progressing well with the PROPEL registry for Catalyst and fully enrolled the TOP FUSION study. This progress is more important than the Q1’22 sales, and makes us more confident about the long-term prospects of commercial success with Catalyst.
5/25/2022 8:31:41 AM - OssDsign: Ljusning i sikte - Penser - Rapportkommentar OssDsign släppte under gårdagen sin Q1-rapport. Försäljningen kom in på 7,1 mkr (6,0), vilket representerar en organisk tillväxt om 10% y/y. I kölvattnet av coronapandemin tyngdes försäljningen av en fortsatt låg nivå av elektiva kirurgiska ingrepp på den amerikanska marknaden. Sedan mars har dock aktiviteten ökat och vi förväntar oss att se en god försäljningsutveckling q/q under den resterande delen av 2022.
5/25/2022 8:15:39 AM - OssDsign Q1: An undramatic first quarter - Redeye - Redeye regards OssDsign’s Q1 as a relative non-event quarter; elective surgeries took a major toll in the early months of Q1, but the lower-than-anticipated sales for OssDsign do not render any case reconsiderations, we argue.
5/16/2022 5:39:13 AM - OssDsign: Good things take time (to produce) - ABG - Softer Q1 on long lead-times dampening sales<br> High surgical activity bodes well for rest of ‘22e <br> Fair value range of SEK 8-21 /share unchanged
4/4/2022 11:59:19 AM - Första patienten har inkluderats i Ossdsigns multicenterregister Propel - Life science-investmentbolaget Karolinska Development meddelar att den första patienten nu har inkluderats i portföljbolaget Ossdsigns prospektiva multicenterregister Propel för fusion av kotor i ryggraden i USA.
3/1/2022 10:04:54 AM - OssDsign: Tillväxtresan fortsätter - Penser - Rapportkommentar Q4 OssDsign släppte under förra veckan sin rapport för det fjärde kvartalet. Försäljningen för kvartalet kom in på 9,2 mkr, med ett rörelseresultat om -24,3 mkr. På helårsbasis var siffrorna i linje med våra estimat med en försäljning om 31,7 mkr (EPB: 31,0) och rörelseresultat om -89,3 mkr (EPB: -84,0).
2/23/2022 10:25:56 AM - OssDsign: Robust performance in challenging conditions - ABG - Sales 4% higher than expected, but EBIT 4% below<br> Weak electives in Q1’22, pushing volumes back<br> Trading below our fair value range of SEK 8-21 per share
2/23/2022 9:03:39 AM - OssDsign: Q4 suggests financial estimates revisions - Redeye - Redeye returns with a more detailed take on the Q4’21 report. We lower our sales estimates considerably more than initially expected while also upping certain costs. This renders a new fair value range.
2/23/2022 8:22:59 AM - OssDsign - Se presentation av Q4 2021 i efterhand - OssDsign presenterade den 22/2 bolagets Q4-rapport för 2021. Det går nu bra att se hela presentationen i efterhand via länken nedan.
2/22/2022 10:24:07 AM - OssDsign Q4: A solid quarter lining up for further growth - Redeye - Redeye notes another quarter where OssDsign delivers record sales, which were more or less in line with our estimates, but with costs higher than expected. We will return with an update following the Q4 presentation and are leaning towards a small downwards change in our fair value range.
12/17/2021 10:22:30 AM - OssDsign: Agreement with Vizient - Redeye - Redeye is glad to see OssDsign signing an agreement with GPO giant Vizient, further strengthening our thesis of accelerated sales growth in the coming years. We reiterate our Base Case at SEK 17 per share.
12/2/2021 9:36:32 AM - OssDsign: On the right track, but estimate changes called for - Redeye - Redeye revisits its estimates for OssDsign in the coming years following the Q3 report, which continued to show progression, though sales were somewhat below our expectations. While we see an attractive growth case ahead and a significant upside potential to or Base Case, we downward adjust our sales projections and valuation slightly.
11/18/2021 9:47:40 AM - OssDsign: Fortsatt bra momentum - Penser - Q3-rapport i linje med våra förväntningar Försäljningen i kvartalet kom in på 8,9 mkr (6,5 i Q3'20), motsvarande en organisk tillväxt om 39%. Det är fortsatt bolagets produkt Cranial (kranieimplantat) som driver försäljningen, men vi räknar med att Catalyst (syntetiskt bengraftssubstitut) kommer börja bidra från och med Q4'21.
11/17/2021 12:04:01 PM - OssDsign Q3: Continues to support the case - Redeye - Redeye notes another record quarter for OssDsign where US sales have leaped forward, boosting gross margins to c.80%. The report continues to support our take on the case, while the market still fails to recognize the fundamental value we see in the company. However, we will shortly publish an update with some downwards estimate changes (negative corona effects persistent) but do not expect any significant impact on our current Fair Value Range.
11/16/2021 8:50:47 AM - OssDsign: Vd Morten Henneveld och CFO Anders Svensson presenterar Q3 - Vd Morten Henneveld och CFO Anders Svensson presenterar bolagets delårsrapport för det tredje kvartalet i en webcast tillsammans med Finwire Media.
10/7/2021 6:19:56 AM - Ossdsign Catalyst har använts vid behandling av patienter i USA - Ossdsign, som är ett av Karolinska Developments portföljbolag, meddelar att de första patienterna i USA behandlats med bengraften Ossdsign Catalyst. Det framgår av ett pressmeddelande.
10/4/2021 6:23:38 AM - Ossdsign får utökat marknadsgodkännande i USA för produkten OssDsign Cranial PSI - Ossdsign har erhållit ett utökat marknadsgodkännande för sin kranialimplantatprodukt OssDsign Cranial PSI från den amerikanska läkemedelsmyndigheten FDA. Det framgår av ett pressmeddelande.
9/8/2021 1:58:19 PM - Ossdsign: First patient enrolment of TOP FUSION - Redeye - Redeye endorses OssDsign's advancement in its clinical study for Catalyst (TOP FUSION), as the first of 17 patients has been enrolled. We still expect first sales to be generated in the US for said product this year but emphasize that adding clinical data supports its chances of a more successful and broader commercialization in the longer term.
9/7/2021 9:14:26 AM - Ossdsign: Designat för fortsatt tillväxt - Penser - OssDsigns rapport för det andra kvartalet innehöll inga större överraskningar. Vi har tagit ned våra försäljningsestimat något på kort sikt, men anser att de långsiktiga tillväxtförutsättningarna består. På kort sikt bedömer vi att Cranial kommer att vara tillväxtdrivaren i bolaget, men den långsiktiga potentialen ser vi inom ortobiologi och produkten Catalyst - tack vare skalbarheten i produkten.
8/19/2021 8:47:38 AM - Ossdsign Q2: An eventful quarter lining up for long-term growth - Redeye - Redeye comments on OssDsign’s Q2 report and emphasizes that activities during and after the quarter continue to support our favorable view on the case. However, we take a more careful stance on the sales ahead, slightly downing our projections for the coming years, though unaffecting our Fair Value Range.
8/17/2021 1:54:59 PM - OssDsign: Webcast efter delårsrapport med vd Morten Henneveld - Medicinteknikbolaget Ossdsigns vd Morten Henneveld presenterar bolagets delårsrapport för det andra kvartalet i en webcast hos Finwire Media.
8/16/2021 1:58:36 PM - Karolinska Developments portföljbolag Ossdesign har lanserat bengraftsubstitutet Catalyst i USA - Life science-investmentbolaget Karolinska Developments portföljbolag Ossdsign har lanserat bengraftsubstitutet Catalyst i USA. Det framgår av ett pressmeddelande.
8/12/2021 5:35:21 AM - Ossdsign: Collaboration with Red One Medical - Redeye - Redeye endorses the latest news surrounding OssDsign’s continuing expansion of its commercial network. Recently, the company entered a collaboration with the Veteran’s Affairs’ and Department of Defense’s private sector partner, Red One Medical. This sends a powerful signal about its clinical relevance in addition to strengthening our confidence in its abilities to increase sales in the coming years.
7/6/2021 1:10:44 PM - Ossdsign: Agreement with Premier - Redeye - Redeye endorses OssDsign’s agreement with the GPO giant Premier, which boosts our confidence in our sales estimates, lining up the company as a growth story. Agreements with GPOs are a key strategy for many Medtech companies to drive sales growth, and we are very pleased with the company now tying itself to one of the largest GPOs in the US.
5/14/2021 6:22:29 AM - Ossdsign: Rights issue and over-allotment option raised SEK 270m - Redeye - Redeye returns with a take on the outcome of OssDsign’s rights issue and exercised over-allotment option, raising a total of SEK 270m before transaction costs. We are encouraged by the interest in the capital raise and believe the share will likely see a reignited momentum in the shorter term.
4/20/2021 9:13:30 AM - Ossdsign: Finansierade för tillväxt - Penser - I spåren av att OssDsign beslutat om att förstärka balansräkningen genom en företrädesemission om ca 240 mkr, vilken är säkerställd genom tecknings- och garantiåtaganden, har den våta filt som legat över aktien till följd av den pressade balansräkningen börjat torka upp. Detta ska möjliggöra för OssDsign att nå målen om positivt kassaflöde 2024, samt omsättning på 300-400 mkr år 2025 i strategin som benämns ASCENT25.
4/7/2021 6:58:31 AM - Lancelot Avalon ökade 2,0 procent i mars - köpt aktier i Rugvista och Sandvik - Fonden Lancelot Avalon steg 2,0 procent i mars, vilket var sämre än fondens jämförelseindex som steg 8,2 procent. Sedan årsskiftet har fonden avkastat 14,4 procent och är därmed bättre än index som har ökat 14,3 procent. Det framgår av en månadsrapport från fondens förvaltare Erik Bertilsson.
4/6/2021 6:11:20 AM - Ossdsign: Strengthening the balance sheet to take on next steps - Redeye - Redeye returns with a review of OssDsign following its announced rights issue and recently presented strategy update – ASCENT25. We are encouraged by its intensified focus on its neurosurgery product portfolio and its new, though adjacent, vertical in spine, strengthening our already favourable view on its longer-term prospects.
3/4/2021 7:47:57 AM - OssDsign: Summary of the Strategy Update Event and comments on the rights issue - Redeye - Redeye returns with a summary of OssDsign’s Strategy Update held at Redeye on March 2nd, as well as a brief comment on the equity issue aiming to raise SEK 240-270m. We are pleased to see that the company accelerates its efforts to reach its full potential, both with its cranial implant and the new vertical in orthobiologics.
12/10/2020 6:59:37 AM - Erik Pensers mäklarchef lyfter fram Ossdsign och Bioservo - Di - Erik Pensers mäklarchef Oskar Ekman lyfter fram Ossdsign och Bioservo som intressanta bolag som kan bli börsraketer. Det rapporterar Dagens industri.
11/12/2020 3:51:51 PM - Styrelseledamot köper aktier för över 180 000 kronor i Ossdsign - Anders Qvarnström har under gårdagen, den 11 november, köpt 12 000 aktier i Ossdsign där han är styrelseledamot. Aktierna köptes till kursen 15,09 kronor per aktie. Köpesumman uppgår till 181 098 kronor. Det framgår av Finansinspektionens insynsregister.
11/12/2020 12:27:56 PM - Ossdsigns styrelseordförande köper 17 500 aktier - Simon Cartmell har idag den 12 november köpt 17 500 aktier i Ossdsign där han är styrelseordförande. Aktierna köptes till kursen 15,20 kronor per aktie. Köpesumman uppgår till 266 077 kronor.
11/12/2020 11:10:56 AM - Ossdsigns septembersiffror talar för en stark avslutning på året - Penser Access - Penser Access har justerat upp sina försäljningsprognoser för Ossdsign med 4 procent efter att bolaget redovisat sitt resultat för det tredje kvartalet igår. Detta då septembersiffrorna talar för en stark avslutning på året. Det framgår av en uppdragsanalys.
11/11/2020 3:04:28 PM - Ossdsign ser ingen förändring i underliggande efterfrågan pga av covid-19 - vd - Ossdsign bedömer inte att den underliggande efterfrågan har ändrats när antalet covid-19 fall ökar i flera marknader runt om i världen. Samtidigt har osäkerheten ökat på grund av ökningen. Det säger bolagets vd Morten Henneveld i samband med dagens webcast.
11/11/2020 7:37:42 AM - Ossdsigns definitiva resultat helt i linje med preliminära uppgifter - Ossdsign redovisar ökande omsättning under tredje kvartalet jämfört med samma period året innan. Rörelseförlusten minskade. Utfallen överensstämmer med de preliminära uppgifterna som presenterades i förra veckan.
11/4/2020 8:00:06 AM - Ossdsign förvärvar och genomför riktad nyemission om 65 miljoner kronor, utspädningseffekt 20 procent - Ossdsign förvärvar Sirakoss som är verksamt inom bengraftsubstitut. Det ger företaget omedelbar tillgång till en femfaldigt större adresserbar marknad.
10/14/2020 9:24:06 AM - Forskningsartikel om Ossdsign har publicerats i vetenskapliga tidsskriften PNAS - En forskningsartikel om Ossdsigns regenerativa implantat har nyligen publicerats i den vetenskapliga tidskriften Proceedings of the National Academy of Sciences of the United States.
9/18/2020 2:13:38 PM - Ossdsign får amerikanskt patentgodkännande relaterat till Cranial PSI - Karolinska Developments portföljbolag Ossdsign får ett amerikanskt patentgodkännande relaterat till designen av bolagets produkt Cranial PSI. Det framgår av ett pressmeddelande.
8/21/2020 6:02:14 AM - Ossdsign: Väntat hack i kurvan Q2'20, men tillväxten fortsätter - Penser - Vi förväntar oss att återhämtningen från botten i april fortsätter från sommaren in i höst, dels drivet att det uppdämda behovet av operationer, men även till följd av bidraget från nya marknader för OssDsign som Frankrike, och från och med september även Japan. Från och med då med Morten Henneveld vid rodret som ny VD. Vi ser ett motiverat värde kring 40 kr per aktie, med möjlighet till större uppsida på ett par års sikt. OssDsign flaggar även för att de kommer att behöva ytterligare kapital inom 12 månader. Vi har justerat upp våra försäljningsprognoser marginellt efter rapporten.
11/25/2019 8:10:15 PM - OssDsign: Lösningen på ett mångtusenårigt problem – Penser - OssDsign: Lösningen på ett mångtusenårigt problem – Penser
5/21/2019 7:28:12 AM - Ossdsigns listningsemission blev övertecknad - Ossdsigns listningsemission blev övertecknad
5/14/2019 2:47:24 PM - Börsplus ger ett neutralt råd för noteringsaktuella Ossdsign - Börsplus ger ett neutralt råd för noteringsaktuella Ossdsign